

FEED Jumps 51% Pre-Market as ENvue Medical Expands Hospital Footprint, But Series H Conversion Overhang Looms

March 24, 2026 — 9:19 AM EDT · Report #27 · Free Equity Reports Research

SUMMARY

ENvue Medical surges on Detroit hospital deal expanding its feeding tube navigation platform to 39 hospitals, but Series H preferred shares create 800% dilution overhang.

SINCE REPORT -42.1%

DATA BOX

Price	\$2.16
Change	+51.05%
Volume	202.7K
Float	~1.1M shares
Mkt cap	\$1.56M

Key Data (9:18 AM ET, March 24, 2026):

- Price: \$2.16 (pre-market)
- Previous Close: \$1.43

- Change: +51.05%
- Volume: 202.7K
- Market Cap: \$1.56M
- Float: Extremely low

FEED is ripping 51% in pre-market after ENvue Medical announced expansion within a major Southeast Michigan health system, bringing the company's U.S. hospital footprint to 39 hospitals. A 714-bed teaching hospital and Level I Trauma Center in Detroit purchased the ENvue Navigation Platform and feeding tubes, marking another win for the FDA-cleared electromagnetic navigation system.

The move validates ENvue's commercial momentum. Revenue grew 12% to \$2.56 million in 2024, while the company has systematically built distribution partnerships and expanded its hospital presence since rebranding from NanoVibronix in December 2025. The January distribution agreement with U-Deliver for ENFit syringes and today's hospital announcement suggest real traction in clinical settings.

But here's the risk most traders aren't seeing in the filings: ENvue has registered 7,962,279 shares for resale, including 2,377,533 shares from Series H Convertible Preferred conversions, 584,796 warrant shares, and up to 4,999,950 dividend shares. Against just 1,088,192 common shares outstanding as of December 5, 2025, this represents potential dilution of over 800%.

The Series H structure is particularly concerning. Each preferred share has \$1,000 stated value, converts at \$7.01 per share (down from a previous floor), and pays 9% annual dividends in stock. In January, ENvue removed the conversion floor price in exchange for holders committing \$2.5 million

additional investment — effectively allowing unlimited dilution at current price levels.

Alpha Capital Anstalt controls these preferred shares and maintains beneficial ownership limitations of 4.99% or 9.99% — classic toxic financing structure where the holder converts and sells into any price strength while maintaining their ownership percentage.

The technical setup screams loaded spring meeting brick wall. FEED carries 50% volatility and 4.16 beta, meaning any volume spike creates violent moves. The stock hit an all-time low of \$0.99 in January, and fell 35% over the past month before today's gap.

Hospital expansion is real, but the math is brutal. The company burned \$3.71 million in losses last year while carrying a \$2.6 million market cap. Free cash flow of negative \$2 million quarterly means the Series H holders aren't just holding for dividends — they need liquidity.

What to watch: Any sustained move above \$2.50 could trigger short covering given the tiny float, but the conversion overhang makes every rally suspect. The real test is whether institutional buyers will step in for the navigation platform technology or if retail gets trapped holding bags when Alpha Capital converts into strength.

Management talks about “strategic account expansion” and hospitals wanting “real-time visualization”, but the Series H terms suggest they're more focused on staying alive than building sustainable value.

This is a classic small-cap momentum trap: legitimate technology meeting death-spiral financing. Trade the volatility if you must, but don't confuse hospital wins with investment viability.

Risk disclosure: ENvue Medical carries substantial dilution risk from outstanding convertible securities and warrants.

This report is for informational purposes only and does not constitute investment advice. Always conduct your own due diligence before making any investment decision.

freeequityreports.com/reports/feed-envue-medical-hospital-expansion-dilution-risk-2026-03-24/ · Free Equity Reports Research · March 24, 2026 · Not investment advice.